Figure 6.

The efficacy and survival with naked virus treatment in naïve mice. (a) Naïve intraperitoneal MC38-luc tumor bearing mice were treated on day 7 with either vvDDr or vA34R i.p. and their survival was followed over time. Bioluminescent images taken on day 16 show a greater reduction in tumor burden in the vA34R-treated groups. (b) Kaplan–Meier survival analysis shows vA34R-treated mice displayed significantly prolonged survival compared with mock-treated control mice (median survival, 48 versus 25 days, P < 0.001) and vvDDr-treated mice (median survival, 48 versus 32 days, P < 0.005).